Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Liver abscess in advanced hepatocellular carcinoma after sorafenib treatment.

Shin SK, Jung YK, Yoon HH, Kwon OS, Kim YS, Choi DJ, Kim JH.

Korean J Gastroenterol. 2014 Jan 25;63(1):47-50.

2.

Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?

Faivre S, de Gramont A, Raymond E.

Target Oncol. 2016 Aug;11(4):565-7. doi: 10.1007/s11523-016-0427-8. No abstract available.

PMID:
26996978
3.

Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma.

Tajiri K, Nakajima T, Kawai K, Minemura M, Sugiyama T.

Intern Med. 2015;54(6):597-600. doi: 10.2169/internalmedicine.54.3675. Epub 2015 Jan 15.

4.

Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.

Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di Costanzo F, Marra F.

World J Gastroenterol. 2014 Jan 21;20(3):786-94. doi: 10.3748/wjg.v20.i3.786.

5.

Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.

Poullenot F, Bioulac-Sage P, Laumonier H, Saric J, Carteret T, Blanc JF.

Acta Oncol. 2014 Mar;53(3):420-3. doi: 10.3109/0284186X.2013.795286. Epub 2013 May 29. No abstract available.

PMID:
23713857
6.

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.

Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.

Liver Int. 2013 Jul;33(6):950-7. doi: 10.1111/liv.12168. Epub 2013 Apr 21.

PMID:
23601249
7.

Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.

Jeong SW, Jang JY, Shim KY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim JH.

Gut Liver. 2013 Nov;7(6):696-703. doi: 10.5009/gnl.2013.7.6.696. Epub 2013 Aug 14.

8.
9.

Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.

Liu D, Liu A, Peng J, Hu Y, Feng X.

Eur J Med Res. 2015 Feb 4;20:12. doi: 10.1186/s40001-015-0085-9. Review.

10.

[Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].

Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Okusaka T.

Nihon Shokakibyo Gakkai Zasshi. 2012 Aug;109(8):1346-54. Review. Japanese. No abstract available.

PMID:
22863957
11.

Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.

Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, Hong T, Strasser SI, Bell S, Ryan M, Nicoll A, Lubel J, Gow PJ, Fink MA, Roberts S, Kemp W, Kronborg I, Arachchi N, Knight V, Dev A.

Scand J Gastroenterol. 2016 Aug;51(8):979-85. doi: 10.3109/00365521.2016.1166518. Epub 2016 May 10.

PMID:
27161568
12.

Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.

Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H, Shimose S, Shirono T, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan.

Cancer Med. 2015 Dec;4(12):1836-43. doi: 10.1002/cam4.548. Epub 2015 Oct 16.

13.

Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.

Elleuch N, Ennaifer R, Romdhane H, Cheikh M, Hefaiedh R, Bougassas W, Ben Nejma H, BelHadj N.

Tunis Med. 2015 Jun;93(6):350-2.

14.

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S.

Oncologist. 2014 Apr;19(4):394-402. doi: 10.1634/theoncologist.2013-0114. Epub 2014 Mar 20.

15.

Sorafenib: 10 years after the first pivotal trial.

Gadaleta-Caldarola G, Infusino S, Divella R, Ferraro E, Mazzocca A, De Rose F, Filippelli G, Abbate I, Brandi M.

Future Oncol. 2015;11(13):1863-80. doi: 10.2217/fon.15.85. Review.

PMID:
26161924
16.

Abdominal Distension in a Patient With Hepatocellular Carcinoma. Benign Pneumatosis Intestinalis and Pneumoperitoneum Associated With Sorafenib Therapy.

Huang YH, Siao FY, Yen HH.

Gastroenterology. 2015 Aug;149(2):e12-3. doi: 10.1053/j.gastro.2014.12.045. Epub 2015 Jun 27. No abstract available.

PMID:
26123559
17.

A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma.

Shen A, Tang C, Wang Y, Chen Y, Yan X, Zhang C, Liu R, Wei X, Zhu Y, Zhang H, Wu Z.

J Clin Gastroenterol. 2013 Nov-Dec;47(10):871-80. doi: 10.1097/MCG.0b013e3182a87cfd. Review.

PMID:
24100749
18.

Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.

Lee SH, Song IH, Noh R, Kang HY, Kim SB, Ko SY, Lee ES, Kim SH, Lee BS, Kim AN, Chae HB, Kim HS, Lee TH, Kang YW, Lee JD, Lee HY.

BMC Cancer. 2015 Apr 8;15:236. doi: 10.1186/s12885-015-1273-2.

19.

Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.

Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T.

World J Gastroenterol. 2014 Sep 21;20(35):12581-7. doi: 10.3748/wjg.v20.i35.12581.

20.

Supplemental Content

Support Center